← Back to Search

Implantable Device

CyPass Micro-Stent for Cataract (COMPASS XXT Trial)

N/A

Waitlist Available

Research Sponsored by Alcon Research

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up month 3, month 6, month 12 (year 1), month 24 (year 2), month 36 (year 3), month 48 (year 4), month 60 (year 5), month 96 (year 8), month 108 (year 9), month 120 (year 10)

Awards & highlights

COMPASS XXT Trial Summary

This trial looks at the long-term effects of the CyPass Micro-Stent on the cornea ten years after implantation.

Eligible Conditions

Cataract
Glaucoma

COMPASS XXT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ month 3, month 6, month 12 (year 1), month 24 (year 2), month 36 (year 3), month 48 (year 4), month 60 (year 5), month 96 (year 8), month 108 (year 9), month 120 (year 10)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~month 3, month 6, month 12 (year 1), month 24 (year 2), month 36 (year 3), month 48 (year 4), month 60 (year 5), month 96 (year 8), month 108 (year 9), month 120 (year 10)

This trial's timeline: 3 weeks for screening, Varies for treatment, and month 3, month 6, month 12 (year 1), month 24 (year 2), month 36 (year 3), month 48 (year 4), month 60 (year 5), month 96 (year 8), month 108 (year 9), month 120 (year 10) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Annualized Percent Rate of Change in Central Endothelial Cell Density (ECD) at Each Year of Observation Reported by Mean and 95 Percent Confidence Interval

Annualized Percent Rate of Change in Central Endothelial Cell Density (ECD) at Each Year of Observation Reported by Mean and Standard Deviation

Annualized Rate of Change in Central Endothelial Cell Density (ECD) at Each Year of Observation Reported by Mean and 95 Percent Confidence Interval

+60 more

COMPASS XXT Trial Design

1Treatment groups

Experimental Treatment

Group I: Cataract Surgery + CyPassExperimental Treatment2 Interventions

CyPass Micro-Stent implanted at the conclusion of cataract surgery (COMPASS trial)

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cataract Surgery

2010

Completed Phase 4

~5370

CyPass Micro-Stent

2013

N/A

~2030

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Alcon ResearchLead Sponsor

707 Previous Clinical Trials

124,783 Total Patients Enrolled

116 Trials studying Cataract

20,678 Patients Enrolled for Cataract

Clinical Operations Lead, SurgicalStudy DirectorAlcon Research, LLC

1 Previous Clinical Trials

124 Total Patients Enrolled

1 Trials studying Cataract

124 Patients Enrolled for Cataract

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the opportunity for participation in this experiment currently available to volunteers?

"Affirmative. A perusal of the information on clinicaltrials.gov reveals that enrollment for this experiment, which was originally posted on December 21st 2020, is still open. The trial requires 374 participants from 3 different sites to be fully recruited."

Answered by AI

How many individuals are participating in the research project?

"Affirmative. According to clinicaltrials.gov, the trial is still recruiting participants and was first posted on December 21st 2020 with a last edit date of May 2nd 2022. 374 patients need to be enrolled from 3 different locations in order for the research to proceed as intended."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent

2020. "Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04629521.